Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar.
Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.
ICYMI Leader Board
Adavale Resources (ASX:ADD) has sketched out exploration plans for its Kabanga Jirani nickel project, with the aim to follow up on work carried out in 2023 while testing a wealth of regional targets generated by previous geophysical surveys.
Viridis Mining and Minerals’ (ASX:VMM) focus at Colossus is on the ‘Alkaline Complex’ within the project area, where drilling from 109 auger holes has produced assays of up to 9,447ppm total rare earth oxides (TREO), driving the next phase of work towards a maiden resource estimate (MRE).
Sunshine Metals (ASX:SHN) has completed farm-in and joint venture agreements with Rockfire Resources PLC (LON:ROCK) for the Lighthouse tenements, which are now part of the consolidated Ravenswood West project near Carter Towers in North Queensland.
Harvest Technology Group (ASX:HTG) has had a win with the ATO, and would like everyone to know that it has pocketed a cheque for $1.67 million in relation to the Group’s R&D Tax Incentive Rebate for the 2023 financial year.
More Top Small Cap Stories: Friday
Cobalt Blue Holdings (ASX:COB) has given the market an update on how things are progressing for its proposed Cobalt Nickel Refinery, noting that two bulk samples (up to 5 tonnes each) of third-party feedstock have now been received at the Broken Hill Demonstration Plant and are undergoing evaluation that will inform major decisions around commercial feedstock for the refinery.
Mantle Minerals (ASX:MTL) announced an upgrade to the Mineral Resource Category at the Highway Deposit, within the Pardoo Ni-Cu Project in the Pilbara region of northern Western Australia, which has grown to 16,463,300 tonnes at 0.407% Ni, 0.117% Cu and 0.032% Co for 67,005 Ni tonnes and 19,208 tonnes Cu.
Mesoblast (ASX:MSB) announced today that the US FDA has granted its allogeneic cell therapy Revascor (rexlemestrocel-L) a Rare Pediatric Disease (RPD) Designation following results from the randomised controlled trial in children with a potentially life-threatening congenital heart condition called hypoplastic left heart syndrome (HLHS).
Bluebet (ASX:BBT) climbed today in the aftermath of an investors call to present the company’s quarterlies live over the telephone. Modern tech is incredible.
Imugene (ASX:IMU) let the market know, via an announcement that requires a medical degree to understand, that the trial of its novel cancer-killing virus CF33-hNIS (aka VAXINIA) has reached the bit where they start pushing trial dosages higher to make sure no one is going to explode or see any other ghastly side effects.
The post In Case You Missed It: A thing, a different thing and an amusing play on words, I guess appeared first on Stockhead.
+ There are no comments
Add yours